NCT06267573

Brief Summary

Evaluation of the effectiveness of the different modalities for treatment of thoracoabdominal aortic aneurysms. FEVAR and BEVAR devices are widely used now due to its feasability and wide range of use . We aim to evaluate the effectiveness of these new devices in the management of TAAA

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
2mo left

Started Sep 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Sep 2024Sep 2026

First Submitted

Initial submission to the registry

February 12, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2025

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2026

Expected
Last Updated

February 20, 2024

Status Verified

February 1, 2024

Enrollment Period

1 year

First QC Date

February 12, 2024

Last Update Submit

February 19, 2024

Conditions

Thoracoabdominal Aortic Aneurysm

Outcome Measures

Primary Outcomes (1)

  • Successful cannulation of the target vessels with complete in-line flow to target organs.

    No ischemia

    Two years

Interventions

Fenestrated and branched endovascular devices for TAAADEVICE

Devices for TAAA

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients

You may qualify if:

  • all adult consecutive patients presenting with TAAA larger than 5.5 cm

You may not qualify if:

  • active infection Asymptomatic patients with small aneurysms Allergy to contrast agents

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Aortic Aneurysm, Thoracoabdominal

Condition Hierarchy (Ancestors)

Aortic Aneurysm, AbdominalAortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

February 12, 2024

First Posted

February 20, 2024

Study Start

September 1, 2024

Primary Completion

September 15, 2025

Study Completion (Estimated)

September 10, 2026

Last Updated

February 20, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share